Bristol-Myers Squibb is Healthy

Bristol-Myers Squibb Logo

Bristol-Myers Squibb (BMY) stock has been going up over the last 7 months and it has hit the top of its 52 week range of $24.97 to $31.93. The company is performing well and has topped the S&P 500 as well as the health care index.

The company is developing new medicines to cure hepatitis and cancer among other things. These will offset the revenue flow from medicines whose patents are about to expire. Bristol-Myers Squibb apparently is doing well at R&D because it has got many potential drugs in its pipelines, some already approved by the FDA.

BMY is also very profitable and has a P/E of 15.20 which is slightly on the high side. It also has a 4.2 % dividend yield which is good. During the last 5 years, BMY has also had a 15% average annual earnings growth.

Some major managers are: Joseph C. Caldarella the Senior VP and Controller; Dr. Elliott Sigal the Chief Scientific Officer and President of R&D; Sanda Leung, the General Counsel; and Frances Cuss, the Senior VP of R&D.

You might want to analyze this stock as potential portfolio acquisition.

About Peter Jefferson

Peter Jefferson is a full-time researcher for, a task he took on in 2011 when the site was launched. He brings to the position a wealth of practical experience in the field of fiscal policy, having consulted with various government bodies on revenue collection, expenditure and economic growth. Contact Peter at peter[at]